Douglas Joshua

5.7k total citations
65 papers, 1.7k citations indexed

About

Douglas Joshua is a scholar working on Hematology, Oncology and Immunology. According to data from OpenAlex, Douglas Joshua has authored 65 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Hematology, 24 papers in Oncology and 23 papers in Immunology. Recurrent topics in Douglas Joshua's work include Multiple Myeloma Research and Treatments (36 papers), T-cell and B-cell Immunology (14 papers) and Immunotherapy and Immune Responses (12 papers). Douglas Joshua is often cited by papers focused on Multiple Myeloma Research and Treatments (36 papers), T-cell and B-cell Immunology (14 papers) and Immunotherapy and Immune Responses (12 papers). Douglas Joshua collaborates with scholars based in Australia, United States and Spain. Douglas Joshua's co-authors include John Gibson, Ross Brown, P. Joy Ho, Hayley Suen, Joy Ho, Shihong Yang, Christian Bryant, Derek N.J. Hart, Daniel Sze and James Favaloro and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Douglas Joshua

64 papers receiving 1.7k citations

Peers

Countries citing papers authored by Douglas Joshua

Since Specialization

Citations

This map shows the geographic impact of Douglas Joshua's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas Joshua with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas Joshua more than expected).

Fields of papers citing papers by Douglas Joshua

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas Joshua. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas Joshua. The network helps show where Douglas Joshua may publish in the future.

Co-authorship network of co-authors of Douglas Joshua

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas Joshua. A scholar is included among the top collaborators of Douglas Joshua based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas Joshua. Douglas Joshua is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Single cell analysis of the CD8<sup>+</sup> T-cell compartment in multiple myeloma reveals disease specific changes are chiefly restricted to a CD69<sup>-</sup> subset suggesting potent cytotoxic effectors exist within the tumor bed. 2023 ·Haematologica ·James Favaloro, Christian Bryant, Edward Abadir, Samuel Rawson Gardiner, Shihong Yang, (unknown), Najah T. Nassif, Lisa M. Sedger, Richard Boyle, Douglas Joshua, P. Joy Ho	2
2	Treatment of patients with Waldenström macroglobulinaemia: clinical practice update from the Myeloma Foundation of Australia Medical and Scientific Advisory Group 2022 ·Internal Medicine Journal ·Dipti Talaulikar, Douglas Joshua, (unknown), John Gibson, Hang Quach, Simon Gibbs, Silvia Ling, Christopher Wård, Bradley Augustson, Judith Trotman, Simon J. Harrison, Constantine S. Tam	1
3	Treg and Oligoclonal Expansion of Terminal Effector CD8+ T Cell as Key Players in Multiple Myeloma 2021 ·Frontiers in Immunology ·Douglas Joshua, Slavica Vučković, James Favaloro, (unknown), Shihong Yang, Christian Bryant, John Gibson, (unknown)	14
4	A liquid biopsy to detect multidrug resistance and disease burden in multiple myeloma 2020 ·Blood Cancer Journal ·Sabna Rajeev Krishnan, Gabriele De Rubis, Hayley Suen, Douglas Joshua, Yiu Lam Kwan, Mary Bebawy	28
5	Excellent outcomes for adolescents and adults with acute lymphoblastic leukemia and lymphoma without allogeneic stem cell transplant: the FRALLE-93 pediatric protocol 2014 ·Leukemia & lymphoma ·Jane S. Hocking, Anthony P. Schwarer, Robin Gasiorowski, (unknown), Sharon Avery, John Gibson, Harry Iland, P. Joy Ho, Douglas Joshua, (unknown), (unknown), (unknown)	15
6	Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma 2014 ·Leukemia & lymphoma ·James Favaloro, (unknown), Ross Brown, Shihong Yang, Hayley Suen, Narelle Woodland, Najah T. Nassif, Derek N.J. Hart, Phillip D. Fromm, Claire Weatherburn, John Gibson, P. Joy Ho, Douglas Joshua	91
7	Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state 2013 ·Leukemia & lymphoma ·James Favaloro, Ross Brown, Esther Aklilu, Shihong Yang, Hayley Suen, Derek N.J. Hart, Phillip D. Fromm, John Gibson, (unknown), P. Joy Ho, Douglas Joshua	64
8	Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma 2012 ·OncoImmunology ·Ross Brown, Hayley Suen, James Favaloro, Shihong Yang, P. Joy Ho, John Gibson, Douglas Joshua	18
9	Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy 2010 ·Blood ·Jia Li, Daniel Sze, Ross Brown, Mark J. Cowley, Warren Kaplan, Sui-Lin Mo, Shihong Yang, Esther Aklilu, (unknown), (unknown), Tetsuo Yamagishi, Yuling Chen, P. Joy Ho, Douglas Joshua	24
10	Regulatory T Cells and Multiple Myeloma 2008 ·Clinical Lymphoma & Myeloma ·Douglas Joshua, Ross Brown, P. Joy Ho, John Gibson	33
11	Quality of Life Related to Oral versus Subcutaneous Iron Chelation: A Time Trade-off Study 2007 ·Value in Health ·Richard H. Osborne, Richard De Abreu Lourenço, Andrew Dalton, (unknown), (unknown), Douglas Joshua, Robert W. Lindeman, (unknown)	55
12	Transformation and progression of Waldenström's macroglobulinemia following cladribine therapy in two cases: natural evolution or iatrogenic causation? 2006 ·American Journal of Hematology ·Silvia Ling, Douglas Joshua, John Gibson, Graham Young, Harry Iland, Geoff Watson, P. Joy Ho	11
13	THE BIOLOGY AND CYTOGENETICSOF MULTIPLE MYELOMA 2002 ·PubMed ·P. Joy Ho, Lynda J. Campbell, John Gibson, Ross Brown, Douglas Joshua	17
14	Hemodialysis: An appropriate therapy in myeloma-induced renal failure 1997 ·American Journal of Kidney Diseases ·Alexandra F. Sharland, (unknown), Douglas Joshua, John Gibson, David J. Tiller	11
15	Nucleoside transporters, bcl‐2 and apoptosis in CLL cells exposed to nucleoside analogues in vitro 1996 ·European Journal Of Haematology ·(unknown), Ross Brown, John Gibson, Belinda Pope, Xiaofeng Luo, (unknown), James S. Wiley, Douglas Joshua	24
16	Myeloma: New aspects of biology, prognosis and treatment 1996 ·Pathology ·Douglas Joshua	2
17	Primary Amyloidosis Co-Presenting with Cervical and Massive Intra-Abdominal Lymphadenopathy 1995 ·Leukemia & lymphoma ·(unknown), John Gibson, Douglas Joshua, H. Kronenberg	5
18	The Use of a Commercially Available Immunoassay to Determine the Level of Interleukin-6 in the Serum of Patients with Myeloma 1991 ·Leukemia & lymphoma ·Ross Brown, Douglas Joshua, (unknown), (unknown), John Gibson	18
19	Multiple myeloma: Relationship between light chain isotype suppression, labelling index of plasma cells, and CD38 expression on peripheral blood lymphocytes 1988 ·American Journal of Hematology ·Douglas Joshua, (unknown), Ross Brown, Susan E. Francis, John Gibson, H. Kronenberg	26
20	Multiple myeloma: the relationship between CALLA (CD10) positive lymphocytes in the peripheral blood and light chain isotype suppression 1987 ·British Journal of Haematology ·(unknown), Douglas Joshua, Ross Brown, H. Kronenberg	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact